interactions with tirzepatide The Revolution: Is Dual Agonism The End Of Single-Pathway Therapy? GlobalRPH Mazdutide vs tirzepatide: comparing dual-agonist

The exception was intended to help a small subset of patients who are unable to take an FDA-approved product for a legitimate medical reason, like an allergy to a preservative or inactive ingredient

10.1056/NEJMoa1509225 78

2024;26(4):24cr03736

These prescriptions are prepared in coordination with licensed providers and made in accordance with pharmacy compounding guidelines

If classified as a generic (rather than a biosimilar likely dependent on whether the drug is synthetic or recombinant), Canadian pricing regulations could require discounts of up to 75% relative to originator products, unlocking new potential for public and private payers to cover the drug at scale